{"id":382656,"date":"2020-11-17T07:03:18","date_gmt":"2020-11-17T12:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382656"},"modified":"2020-11-17T07:03:18","modified_gmt":"2020-11-17T12:03:18","slug":"antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/","title":{"rendered":"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position:inside; }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing<\/b><\/p>\n<p>TORONTO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAntibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it intends to complete a consolidation of its issued and outstanding common shares (\u201cCommon Shares\u201d) on the basis of one (1) new Common Share for every ten (10) Common Shares presently issued and outstanding (\u201cConsolidation\u201d). Completion of the Consolidation remains subject to the approval of the Toronto Stock Exchange (\u201cTSX\u201d) and is expected take effect on or about December 1, 2020.\n<\/p>\n<p>\nAt the Annual and Special Meeting of Shareholders held on August 20, 2020, Antibe\u2019s shareholders re-approved a special resolution authorizing the Board of Directors of the Company to effect the Consolidation to better prepare it for a possible future listing on the NASDAQ or other senior US stock exchange. The Company believes the Consolidation and such a listing would enable Antibe to further broaden its investor base and increase liquidity.\n<\/p>\n<p>\nUpon receipt of TSX approval of the Consolidation, Antibe will provide additional details regarding a new CUSIP number for its Common Shares to distinguish between the pre- and post-consolidated Common Shares. The Company\u2019s name and trading symbol will remain unchanged. If, as a result of the Consolidation, a shareholder becomes entitled to a fractional share, each fractional Common Share that is at least 0.5 of a Common Share will be rounded up to the nearest whole Common Share and each fractional Common Share that is less than 0.5 of a Common Share will be rounded down to the nearest whole Common Share, provided that each shareholder shall receive at least one (1) Common Share post Consolidation. Following the completion of the Consolidation, the Company will have approximately 38,678,280 Common Shares issued and outstanding.\n<\/p>\n<p>\nWarrants issued by Antibe will also be adjusted proportionately in response to the Consolidation. On the effective date of the Consolidation, the exercise of ten (10) Warrants will be required to purchase one (1) post-Consolidation Common Share. The exercise price of the Warrants will be adjusted as of the effective date of the Consolidation as set out in the warrant indentures governing the terms of the Warrants.\n<\/p>\n<p>\nAntibe\u2019s transfer agent, Computershare Investor Services (\u201cComputershare\u201d), will act as the exchange agent for the Consolidation. On the effective date of the Consolidation, Computershare will send instructions (i.e. a Letter of Transmittal) to shareholders who hold the Company\u2019s stock certificates regarding the exchange of old certificates for new certificates, should they wish to do so. Until surrendered, each stock certificate representing pre-Consolidation Common Shares will be deemed for all purposes to represent the number of whole post-Consolidation Common Shares to which the shareholder is entitled as a result of the Consolidation.\n<\/p>\n<p>\nShareholders who hold their Common Shares in brokerage accounts or \u201cstreet name\u201d are not required to take any action to effect the exchange of their Common Shares.\n<\/p>\n<p><b>About Antibe Therapeutics Inc.<\/b><\/p>\n<p>\nAntibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation, safer nonsteroidal anti-inflammatory drugs (\u201cNSAIDs\u201d) for pain and inflammation arising from a wide range of medical conditions. Antibe is developing three assets that seek to overcome the gastrointestinal (\u201cGI\u201d) ulcers and bleeding associated with NSAIDs. Antibe\u2019s lead drug, otenaproxesul (ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-safe alternative to low-dose aspirin. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fantibethera.com%2F&amp;esheet=52329405&amp;newsitemid=20201117005512&amp;lan=en-US&amp;anchor=antibethera.com.&amp;index=1&amp;md5=f55cabd1d91f28b6dfb0c7e1e866845f\">antibethera.com.<\/a><\/p>\n<p><b>Forward Looking Information<\/b><\/p>\n<p>\nThis news release includes certain forward-looking statements under applicable securities laws, which include, but are not limited to, statements about the potential for the US listing, the consolidation of the Company\u2019s shares, and the potential to further broaden the Company\u2019s investor base and gain increased liquidity with respect to the Common Shares with a US listing. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions &#8220;will&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;plan&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;propose&#8221;, \u201clook forward\u201d and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company\u2019s ability to meet all of the quantitative and qualitative listing criteria to list the Common Shares on a US securities exchange; the Company\u2019s ability to satisfy the conditions for a share consolidation; the Company\u2019s ability to broaden its investor base and increase the liquidity of the Common Shares with the US listing; the Company\u2019s ability to execute its business strategy and successfully compete in the market, and the other risks identified in the Company\u2019s public filings made in Canada. The Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201117005512\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201117005512\/en\/<\/a><\/span><\/p>\n<p>\nAntibe Therapeutics Inc.<br \/>\n<br \/>Christina Cameron<br \/>\n<br \/>VP Investor Relations<br \/>\n<br \/>+1 416-922-3460<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:christina@antibethera.com\">christina@antibethera.com<\/a><\/p>\n<p>\nStern Investor Relations<br \/>\n<br \/>Courtney Turiano<br \/>\n<br \/>+1 212-362-1200<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:courtney.turiano@sternir.com\">courtney.turiano@sternir.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201117005512\/en\/718346\/3\/ANTIBE-logo-RGB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing TORONTO&#8211;(BUSINESS WIRE)&#8211; Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it intends to complete a consolidation of its issued and outstanding common shares (\u201cCommon Shares\u201d) on the basis of one (1) new Common Share for every ten (10) Common Shares presently issued and outstanding (\u201cConsolidation\u201d). Completion of the Consolidation remains subject to the approval of the Toronto Stock Exchange (\u201cTSX\u201d) and is expected take effect on or about December 1, 2020. At the Annual and Special Meeting of Shareholders held on August 20, 2020, Antibe\u2019s shareholders re-approved a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-382656","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing TORONTO&#8211;(BUSINESS WIRE)&#8211; Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it intends to complete a consolidation of its issued and outstanding common shares (\u201cCommon Shares\u201d) on the basis of one (1) new Common Share for every ten (10) Common Shares presently issued and outstanding (\u201cConsolidation\u201d). Completion of the Consolidation remains subject to the approval of the Toronto Stock Exchange (\u201cTSX\u201d) and is expected take effect on or about December 1, 2020. At the Annual and Special Meeting of Shareholders held on August 20, 2020, Antibe\u2019s shareholders re-approved a &hellip; Continue reading &quot;Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T12:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing\",\"datePublished\":\"2020-11-17T12:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/\"},\"wordCount\":901,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/\",\"name\":\"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-17T12:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/","og_locale":"en_US","og_type":"article","og_title":"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing - Market Newsdesk","og_description":"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing TORONTO&#8211;(BUSINESS WIRE)&#8211; Antibe Therapeutics Inc (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it intends to complete a consolidation of its issued and outstanding common shares (\u201cCommon Shares\u201d) on the basis of one (1) new Common Share for every ten (10) Common Shares presently issued and outstanding (\u201cConsolidation\u201d). Completion of the Consolidation remains subject to the approval of the Toronto Stock Exchange (\u201cTSX\u201d) and is expected take effect on or about December 1, 2020. At the Annual and Special Meeting of Shareholders held on August 20, 2020, Antibe\u2019s shareholders re-approved a &hellip; Continue reading \"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T12:03:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing","datePublished":"2020-11-17T12:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/"},"wordCount":901,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/","name":"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-17T12:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201117005512r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/antibe-therapeutics-to-complete-share-consolidation-in-preparation-for-potential-nasdaq-listing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Antibe Therapeutics to Complete Share Consolidation in Preparation for Potential NASDAQ Listing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=382656"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382656\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=382656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=382656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=382656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}